Satralizumab approved as first at-home treatment for thyroid eye disease

On October 15, 2026, the FDA approved satralizumab-mwge (Enspryng) as the first at-home subcutaneous treatment for adults with thyroid eye disease (TED). Approval was based on the phase 3 SatraGO-2 trial, where satralizumab achieved a 52.9% proptosis response rate compared to 23.4% for placebo, alongside significant diplopia reduction. Satralizumab inhibits IL-6 receptors and offers a self-administered alternative to existing intravenous therapies, requiring baseline infection screenings.

FDA approval for thyroid eye disease

• ▪On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease
• ▪Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Administration and dosing schedule

• ▪Dr. César A. Briceño of the Scheie Eye Institute stated that satralizumab, an effective subcutaneous option, reduces the logistical burden associated with intravenous infusion therapies for thyroid eye disease
• ▪Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider
• ▪Satralizumab dosing requires three initial loading injections at weeks 0, 2, and 4, followed by maintenance injections every 4 weeks

SatraGO trial program evidence

• ▪Satralizumab's phase 3 SatraGO trial program demonstrated consistent efficacy in an overall trial population that included patients with both active and chronic thyroid eye disease
• ▪The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries
• ▪Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

SatraGO clinical trial findings

• ▪Roche reported that no new safety signals were identified for satralizumab across the phase 3 SatraGO-1 and SatraGO-2 clinical trials
• ▪In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Safety, contraindications, and screening

• ▪Satralizumab is contraindicated in patients with active or untreated latent tuberculosis and active hepatitis B infection
• ▪The most common adverse events reported for satralizumab in the SatraGO-1 and SatraGO-2 clinical trials were upper respiratory tract infections and elevated alanine aminotransferase levels
• ▪Prescribing guidelines for satralizumab require patient screenings for tuberculosis, hepatitis B, and liver transaminase levels prior to administering the first dose

Interleukin-6 inhibition research

• ▪Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition
• ▪Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Neuromyelitis optica spectrum disorder comparison

• ▪Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition
• ▪Roche reported that satralizumab's safety profile in thyroid eye disease trials was consistent with its known profile in neuromyelitis optica spectrum disorder

Other therapies for thyroid eye disease

• ▪Genentech's interleukin-6 inhibitor tocilizumab has been studied off-label as a second-line therapy for patients with moderate-to-severe, glucocorticoid-resistant thyroid eye disease
• ▪Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Thyroid eye disease symptoms and prevalence

• ▪Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding
• ▪Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism